DURAN, I., J. ZIEBA, F. CSUKASI, J. H. MARTIN, D. WACHTELL, M. BARAD, B. DAWSON, Bohumil FAFÍLEK, C. M. JACOBSEN, C. G. AMBROSE, D. H. COHN, Pavel KREJČÍ, B. H. LEE and D. KRAKOW. 4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta. Journal of bone and mineral research. Hoboken: Wiley, 2022, vol. 37, No 4, p. 675-686. ISSN 0884-0431. Available from: https://dx.doi.org/10.1002/jbmr.4501.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name 4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta
Authors DURAN, I., J. ZIEBA, F. CSUKASI, J. H. MARTIN, D. WACHTELL, M. BARAD, B. DAWSON, Bohumil FAFÍLEK (203 Czech Republic, belonging to the institution), C. M. JACOBSEN, C. G. AMBROSE, D. H. COHN, Pavel KREJČÍ (203 Czech Republic, belonging to the institution), B. H. LEE and D. KRAKOW (guarantor).
Edition Journal of bone and mineral research, Hoboken, Wiley, 2022, 0884-0431.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30202 Endocrinology and metabolism
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.200
RIV identification code RIV/00216224:14110/22:00129049
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/jbmr.4501
UT WoS 000748116400001
Keywords in English osteogenesis imperfecta; Aga2; bone; 4-PBA; ER stress; Chop(-/ -); Bip(+/-)
Tags 14110513, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/5/2022 13:26.
Abstract
Osteogenesis imperfecta (OI) is a genetically heterogenous disorder most often due to heterozygosity for mutations in the type I procollagen genes, COL1A1 or COL1A2. The disorder is characterized by bone fragility leading to increased fracture incidence and long-bone deformities. Although multiple mechanisms underlie OI, endoplasmic reticulum (ER) stress as a cellular response to defective collagen trafficking is emerging as a contributor to OI pathogenesis. Herein, we used 4-phenylbutiric acid (4-PBA), an established chemical chaperone, to determine if treatment of Aga2(+/-) mice, a model for moderately severe OI due to a Col1a1 structural mutation, could attenuate the phenotype. In vitro, Aga2(+/-) osteoblasts show increased protein kinase RNA-like endoplasmic reticulum kinase (PERK) activation protein levels, which improved upon treatment with 4-PBA. The in vivo data demonstrate that a postweaning 5-week 4-PBA treatment increased total body length and weight, decreased fracture incidence, increased femoral bone volume fraction (BV/TV), and increased cortical thickness. These findings were associated with in vivo evidence of decreased bone-derived protein levels of the ER stress markers binding immunoglobulin protein (BiP), CCAAT/-enhancer-binding protein homologous protein (CHOP), and activating transcription factor 4 (ATF4) as well as increased levels of the autophagosome marker light chain 3A/B (LC3A/B). Genetic ablation of CHOP in Aga2(+/-) mice resulted in increased severity of the Aga2(+/-) phenotype, suggesting that the reduction in CHOP observed in vitro after treatment is a consequence rather than a cause of reduced ER stress. These findings suggest the potential use of chemical chaperones as an adjunct treatment for forms of OI associated with ER stress. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Links
GA17-09525S, research and development projectName: Neobvyklé signální dráhy lidských receptorových tyrozinových kináz
Investor: Czech Science Foundation
GA19-20123S, research and development projectName: Regulace časného vývoje savčí končetiny pomocí nestabilních morfogenů z rodiny FGF (Acronym: Regulace časného vývoje savčí končetiny)
Investor: Czech Science Foundation
PrintDisplayed: 17/7/2024 07:30